Clinical Trial Update: Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies [Phase 3]

View source ↗

Summary

A Phase 3 protocol update describes monitoring neurological development in infants exposed to tanezumab in utero from birth to 15 months in ongoing clinical stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer Pain
• Low Back Pain
• Osteoarthritis

Drugs mentioned

• Tanezumab (tanezumab)

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis, Cancer Pain | Phase 3 | Status: COMPLETED | Results posted: 2021-06-25